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ABSTRACT 
 
DHEA (3β-hydroxy-androst-5-en-17-one) is a natural steroid prohormone. Despite a lack of 
information on the effect, DHEA and other prohormones are frequently used as a food 
supplement by body-builders. DHEA is suspected for growth promoting abuse in cattle as 
well.  Considering the latter, urine samples from a previous exposure study in which calves 
were exposed to 1 g DHEA per day during 7 days, were used. The calves were divided in 
three groups: one orally treated, one intramuscularly injected and a control group. The effect 
of this treatment on the urinary profile of several precursors and metabolites of DHEA was 
investigated. Urine samples were collected several days before and during the 7 days of 
administration and were submitted to a clean-up procedure consisting of a separation of the 
different conjugates (free, glucuronidated and sulphated forms) of each compound on a SAX 
column (Varian). An LC-MS/MS method was developed for the detection and quantification 
of several metabolites of the pathway of DHEA including 17α- and 17β-testosterone, 4-
androstenedione, 5-androstenediol, pregnenolone and hydroxypregnenolone. Elevated levels 
of DHEA, 5-androstenediol and 17α-testosterone were observed in the free and sulphated 
fraction of the urine of the treated calves, thus indicating that the administered DHEA is 
metabolized mainly by the ∆5-pathway with 5-androstenediol as the intermediate. 
Sulphoconjugates of DHEA and its metabolites were found to constitute the largest proportion 
of the urinary metabolites. The free form was also present, but in a lesser extent than the 
sulphated form, while glucuronides were negligible.  
KEYWORDS: LC-MS/MS, DHEA, metabolites, 5-androstenediol, urine, prohormones   
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INTRODUCTION 
 
 
The EC Directive 96/22 states that substances with hormonal activity are prohibited in cattle 
fattening[1]. Monitoring programs are required to live up to this Directive, thus requiring 
experience in analyzing feed, urine and tissue samples for screening and confirmation of 
hormone residues [2]. In addition, knowledge about absorption, biotransformation and 
excretion kinetics of illegally administered hormonal substances, as well as levels of 
endogenous hormones in livestock, is another requisite [1;3]. Besides steroids, there is a 
tendency in the livestock production towards misuse of feed supplements and preparations 
containing prohormones. The action of these prohormones is based on the conversion into 
more active hormones in target organs, after administration and uptake in the blood 
circulation. This may lead to anabolic action and subsequently improved lean/fat ratios in 
farm animals [4;5]. 
DHEA (Dehydroepiandrosterone, 3β-hydroxy-androst-5-en-17-one) is a natural steroid 
prohormone and is a key intermediate in the biosynthesis of biologically potent androgens and 
estrogens [6;7]. Endogenous steroids can be produced by the means of two alternative 
pathways, the ∆4- and the ∆ 5- pathway, corresponding to the metabolisation of cholesterol to 
pregnenolone and progesterone as the primary precursors and respectively 4-androstenedione 
and DHEA as their intermediates. Starting from DHEA, the conversion to 17β-testosterone 
(figure 1) can be catalyzed by hydroxysteroid dehydrogenases (HSDs) over 4-
androstenedione (mainly in the gonads) or 5-androstenediol (mainly in the adrenal gland) 
[5;8-10]. However, abuse of DHEA, and also other prohormones, has been hard to prove due 
to the incomplete understanding of the DHEA metabolism as well as intra- and inter-
individual variability in urinary steroid excretion [4;11]. Recently, a metabolomics based 
screening strategy has been conducted by Rijk et al.[12] in which several bovines where 
treated with prohormones such as DHEA and pregnenolone. Data were analyzed using 
multivariate statistics followed by identification of signals differential in urine of DHEA-
treated versus control animals. This screening strategy is a useful tool to trace abuse with 
prohormones like DHEA and pregnenolone. However the concentration levels of this 
prohormones remains unknown and therefore a targeted analysis after this untargeted 
approach can be an added value.  
The aim of our study was to focus on the excretion profile of DHEA and its metabolites in 
calf urine after an oral and intramuscular administration of DHEA. It was possible with our 
quantitative method to get an idea of the concentration levels of DHEA and several of its 
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metabolites after intake of DHEA, which was unknown in calves until now. Naturally, DHEA 
is mainly present in blood and urine of older animals in its sulphated form and to a much 
lesser extent in its free form or as a glucuronide conjugate [11]. The sample clean-up was set 
up such that each form, i.e. free, sulphated or glucuronidated form of DHEA and its 
metabolites could be investigated.  
 
 
MATERIALS AND METHODS 
 
Experimental Protocol 
Urine samples were collected according to the study design presented in figure 2. Eight calves 
ranging in age from 6 till 10 months were used in this study, aiming to simulate the actual 
practice. These real-life bovines were housed in stables and normally fed. At two different 
time intervals several calves were allocated to a group and received either an oral treatment 
with DHEA or an intramuscular treatment with DHEA, while others served as controls. 
Treated calves were administered with 1 g of DHEA, orally or intramuscularly, every day for 
seven days. In the first period (june 2005), 1 calf was treated orally, 1 intramuscularly and 3 
served as controls and did not receive any DHEA supplementation. In the second period 
(december 2006), 1 calf was treated orally, 1 intramuscularly and 1 served as a control. 
DHEA treatment was performed in the morning and urine sampling in the late afternoon for 
the first period and just before the next treatment in the second group (period 2). Urine 
samples were collected several days before treatment (5 days before treatment in period 1 and 
on days -20 and -5 before treatment in period 2) and during 7 days of administration in both 
periods. This study was undertaken after approval by the Ethical Committee of Ghent 
University. Samples were collected and frozen at -20°C until analysis. 
 
Reagents and chemicals 
Methanol was high-performance liquid chromatography grade and obtained from VWR 
International (Zaventem, Belgium). Ethyl acetate was purchased from Acros Organics (Geel, 
Belgium), diethylamine from Sigma-Aldrich and Helix pomatia digestive juice (Cat. No. 127 
698; β-glucuronidase activity: 4.5 standard units; arylsulfatase activity: 14 standard units) 
from Boehringer Mannheim (Mannheim, Germany). Water was obtained from a Milli-Q 
Gradient System (Millipore, Bedford, MA, USA). Sodium acetate, glacial acetic acid, formic 
acid, fuming hydrochloric acid 37%, lithium chloride (pro analysis) were purchased from 
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Merck (Overijse, Belgium). Standards of dehydroepiandrosterone (DHEA), 4-androstene-
3,17- dione (AED), 17α-testosterone (α-T), 17β-testosterone (β-T) and pregnenolone (Preg) 
were purchased from Sigma-Aldrich, while 17α-Hydroxypregnenolone (OH-Preg) and 5-
androstene-3β,17β-diol (5-Andro) were obtained from Steraloids (Newport, RI, USA). 17β-
19-Nortestosterone-D3 (NT-D3) and 17α-methyltestosterone-D3 (MT-D3) were supplied by 
RIVM (Bilthoven, The Netherlands). Miglyol 812 (Certa SA, Braine-l’Alleud, Belgium) was 
used for dissolving the DHEA for intramuscular injection. 
 
Preparation of standard solutions 
Stock standard solutions (1 mg.mL-1) of α-T, β-T, AED, 5-Andro, Preg, OH-Preg and DHEA 
were prepared by dissolving 5.0 mg in 5.00 mL of methanol. Stock standard solutions of NT-
D3 and MT-D3 were prepared from ampoules containing 0.1 mg of lyophilised powder by 
adding 1.00 mL of methanol to the ampoules, vortexing and transferring the methanol into a 
glass tube giving standard solutions of 0.1 mg.mL-1. Stock solutions were stored at 4°C and 
had a shell life of at least 1 year. Working standard solutions are prepared by dilution with 
methanol to the appropiate concentrations of 10 and 1 ng.µL-1 and stored at 4°C for maximum 
3 months. From the individual stock standard solutions different standard mixtures were 
prepared and stored at 4°C for 3 months. These standard mixtures were used to create a 
matrix calibration curve. 
 
Materials and apparatus 
Octadecyl (C18) (6 mL, 500 mg) and aminopropyl (NH2) (3 mL, 500 mg) SPE columns were 
purchased from Grace Discovery Sciences (Lokeren, Belgium). The C18-SPE column was 
conditioned by passing through 2 x 5 mL of methanol followed by 2 x 5 mL of water. The 
NH2-SPE column was conditioned by passing through 2 x 3 mL ethylacetate. Bond Elut 
strong anion exchange (SAX) SPE columns were obtained from Varian (Sint-Katelijne 
Waver, Belgium). The SAX column was conditioned by subsequently passing 4 mL 
methanol, 4 mL water, 20 mL of 0.5 M acetic acid in water, 20 mL of water and 5 mL of 
methanol. 
Analysis were performed on a Alliance 2695 HPLC system instrument coupled to a Quattro 
LCZ mass spectrometer (both from Waters, Milford, MA, USA) equipped with the Masslynx 
software for data processing. Chromatographic separation was achieved on a Symmetry C18 
column (2.1 x 150 mm, 5 µm) preceded by a guard column Symmetry C18 (2.1 x 10 mm, 3.5 
µm) (both from Waters, Milford, MA, USA). The column was kept at room temperature (20-
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23°C). The mobile phase consisted of water/MeOH/ formic acid (FA)  (89.7:10:0.3) and 
MeOH/FA (99.7/0.3) using the gradient elution program described in table 1. The injection 
volume was 100 µL. 
The MS/MS operating parameters were obtained and optimized under positive-ion (ESI+) 
mode. Multiple reaction monitoring (MRM) transitions for each analyte were individually 
optimized, an overview of the precursor and product ions used in this MRM method, together 
with the cone voltages and collision energies, is given in table 2. Capillary voltage was set at 
4.8 kV, the extractor at 3 V and high-purity nitrogen was used as spray gas. Source and 
desolvation temperatures were set at 150°C and 350°C respectively. 
 
Separation of the free, glucuronide and sulphate fractions  
The sample clean-up was based on the method descibed by Van Poucke et al. for the 
fractionation of free and conjugated steroids for the detection of boldenone metabolites in calf 
urine [13]. In short, the procedure is as follows: the pH of 10 mL of the urine samples were 
adjusted to 4.6 with 3 M acetate buffer (pH 4.6) and applied onto C18 cartridges. After 
washing with 2 x 5 mL of water and 2 x 5 mL 10% methanol, a preconditioned SAX column 
was placed under the C18 column. The free and conjugated fractions were then eluted with 2 x 
5 mL methanol where only the the conjugated fractions were retained and the free form was 
collected. Next, the glucuronide fraction was eluted from the SAX column with 10 mL FA 
(0.5 M) in methanol. In the third step, a preconditioned C18 cartridge was placed underneath 
the SAX column and the sulphate fraction was eluted from the SAX column with 10 mL 
triethylamine (0.5 M) in water and was trapped onto the C18 column. After washing the C18 
column with 2 x 5 mL water, the suphate fraction was finally eluted with 5 mL of methanol. 
All fractions were then evaporated to dryness at 40°C under nitrogen. 
 
Hydrolysis 
Next, the glucuronide and sulphate fractions were submitted to an hydrolysis step. The 
enzymatic hydrolysis of the glucuronide fractions was achieved by adding 5 mL of a 0.2 M 
acetate buffer (pH 4.6) and 25 µL of a tenfold dilution of Helix Pomatia juice in water. The 
samples were then kept for 2 h at 60°C. For the hydrolysis of the sulphate fraction, the dried 
residue was dissolved in 5 mL of a solvolysis solution consisting of 1 M lithium chloride / 
hydrochloric acid. This samples were kept 1 h at 80°C and afterwards 15 mL of water was 
added and the samples were centrifuged at 2800 g. 
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Final sample clean-up 
The dried residue of the free fraction was redissolved in 10 mL of water. The free fractions 
and the supernatant of the glucuronide and sulphate fractions were then applied onto a C18 
column. Afer washing with 2 x 5 mL of water and 2 x 5 mL 10% methanol, the column was 
dried and placed underneath a preconditioned NH2 column. The columns were then eluted 
with 5 mL of ethyl acetate. The eluates were evaporated to dryness at 40°C under nitrogen. 
The dried residues were each dissolved in 150 µL of mobile phase (methanol/water/FA 
(60/39.7/0.3)). 
 
Quantification and identification 
Matrix calibration curves were performed daily by analyzing 5 blank urines (10 mL) spiked at 
5 different levels in the 1-80 ng.mL-1 range for α-T, β-T, AED, OH-Preg and Preg, the 1-200 
ng.mL-1 range for 5-Andro, and the 1-1000 ng.mL-1 range for DHEA. All urine samples were 
spiked with MT-D3 at a concentration level of 2 ng.mL-1 as an internal standard. The final 
extracts from treated calves were diluted 10 times with the mobile phase and the external NT-
D3 standard was added at the end of the analysis at a concentration of 2 ng.mL-1. Diluted 
extracts of urine samples were only used to quantify the samples that did not fit in the linear 
range of the calibration curve.  
Calibration plots were constructed by applying the least-squares regression model and by 
plotting the response against the hormone concentration. Compounds were only used in the 
data analysis when the criteria of the Commission Decision 2002/657/EC were fulfilled [14] . 
Several urines were analyzed on two different time intervals. The concentrations of all target 
compounds in the entire concentration range differed maximally 30%. 
 
Data analysis 
All results are reported as the mean ± SE (standard deviation) and the median. Data were 
analyzed using a two-way analysis of variance. Non-parametric data were analyzed by means 
of Kruskal-Wallis test. When significant effects were revealed or only two groups were 
examined, an independent t-test or Mann-Whitney test taking account of the Bonferroni 
correction was used to locate the pair wise differences between groups. Spearman’s 
correlations coefficients were calculated to determine significant correlations between the 
concentration of the several hormones and the day of urine collection. P < 0.05 was 
considered as statistically significant. 
All calculations were executed in Excel® or in SPSS®. 
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RESULTS AND DISCUSSION 
Urinary concentrations of DHEA, AED, 5-Andro, α-T, β-T, Preg and OH-Preg in calves were 
investigated before starting the treatment and during the DHEA treatment. Levels of the 
precursors Preg and OH-preg in urines during the entire study were found too low to be 
confirmed and/or quantified. Therefore it is not possible to draw any conclusion about the 
levels of Preg and OH-Preg before and after treatment with DHEA and as a consequence the 
data and statistical processing of these compounds are left out of the discussion. Table 3a 
shows the mean basal concentrations, the median, minimum and maximum value of the target 
analytes in the urines from the 5 calves of group 1 (June 2005) before starting the treatment. 
This was evaluated in order to show whether the treated calves were not calves which already 
excreted higher concentrations of these hormones and which statistically did not differ from 
the control calves at the beginning of the treatment. No significant differences were observed 
in group 1 in the baseline levels of DHEA and its metabolites 5-Andro, α-T, β-T, AED in the 
free or sulphated form. Group 2 (December 2006) did not yield enough data to prove this 
statistically. However, the assumption was made that there was also no significant difference 
in the basal urinary concentrations of these hormones in the 3 calves of group 2, shown in 
table 3b. Despite the large inter- and intravariability in all hormones in free and sulphated 
form, initial basal levels were not statistically different and within the normal range. 
Therefore, the biological variability is not expected to give any problems when comparing the 
control group with the treatment group during the study. However, when comparing the mean 
concentrations and corresponding standard deviations of the two groups (table 3a and 3b), 
slightly higher concentrations of the sulphated form of 5-Andro, α-T and β-T were observed 
in group 2. This was expected as the age of the calves differs between the two groups and was 
part of the general idea of using real-life bovine animals. In group 1 the calves were only 6 
months old in contrast with the calves of group 2 that were already 9 till 10 months of age. 
These observed differences were checked statistically. Therefore basal urinary concentrations 
of all the hormones in free and sulphated form before treatment were compared between the 
group 1 and 2. A statistically significant difference in the levels of sulphated α-T (p=0.027) 
and β-T (p=0.012) was found between group 1 and 2. These results, higher levels of α-T and 
β-T in group 2, are in accordance with results earlier obtained by analyzing urine samples of 
calves and young bovines [3;15]. These studies pointed out that when the two isomers of 
testosterone (α and β) were followed, α-T was the first that appeared in the urine of calves. 
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When the calves got older and turned into young bovines, the concentration of α-T increased 
and low amounts of β-T appeared. 
In a next step baseline levels of the control animals before and during the treatment were 
compared. Because of the proven differences between the two groups for α-T and β-T, data of 
α-T and β-T obtained in group 2 where excluded when comparing the baseline levels of the 
control animals before and during treatment. Table 4 shows the mean concentrations, standard 
deviations, median, minimum and maximum value of the urinary concentrations of the free 
and sulphated forms of DHEA and its metabolites of all control animals before the start of and 
during the study. A small but statistically significant difference in the concentration of the free 
and sulphated form of DHEA (p=0.021) and 5-Andro (p=0.026) was found for which we have 
no explanation. 
Subsequently the influence of the oral and intramuscular treatment with DHEA was 
investigated, looking at DHEA and its metabolites in their sulphated and free form. The 
urinary baseline levels of the sulphated form of DHEA and its metabolites from the control 
group (control) as well as the influence of 1 g DHEA orally (oral) or intramuscularly (IM) 
administered on urinary DHEA metabolites are illustrated in figure 3. Compared to the 
control group the oral treated group differed significantly for the sulphated forms of DHEA 
(p=0.000) and 5-Andro (p=0.000). The intramuscularly treated group differed significantly 
from the control group for the sulphated forms of DHEA (p=0.000), 5-Andro (p=0.000) and 
α-T (p=0.006). These statistically proven differences can clearly be seen in figure 3, but when 
looking at the graphs of α-T, although not proven, a clear increase of α-T after the oral 
treatment can be observed as well. The highest increase was obtained in the concentration of 
the sulphoconjugates of DHEA (DHEAS) (>2000 ng.mL-1), followed by the sulphated forms 
of 5-Andro and α-T (both around 400 ng.mL-1). The 5-Andro metabolite is the intermediate in 
the adrenal gland in the conversion of DHEA to 17β-testosterone immediately derived by the 
action of 17β-hydroxysteroid dehydrogenase [16], while α-T is considered as the main 
metabolite of β-T from the action of 3β-hydroxysteroid dehydrogenase. There was no increase 
in the sulphated form of β-T (figure 3D) and no statistical difference between the orally and 
intramuscularly treated group for these sulphated conjugates could be detected. Figure 4 
summarizes the results of the concentrations of DHEA and its metabolites in the free form of 
the three different treatments: control group (control), orally treated group (oral) and 
intramuscularly treated group (IM). The comparison of the concentrations of DHEA and its 
metabolites of the different groups in the free form differed slightly from the sulphated form. 
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Here there was a statistically significant difference between the control group and the orally 
treated group for DHEA (p=0.000) and α-T (p=0.000), and when comparing the control group 
with the intramuscularly treated group for DHEA (p=0.000), 5-Andro (p=0.001) and α-T 
(p=0.000). The concentration of AED (the metabolite of the ∆ 4-pathway) was a bit higher in 
the orally treated group but could not be statistically proven. The difference for the 
intermediate of the ∆5-pathway (5-Andro) between the oral group and the control group could 
also not be proven statistically in contrast to the comparison of the IM group with the control 
group, but figure 4B shows that this difference is very small. Thus it can be concluded that 
there was no statistical difference between the orally and intramuscularly treated group for 
these free target compounds. Comparing the data from figure 3 and figure 4, it becomes clear 
that the amounts of the free forms are relatively low compared to their sulphated forms. 
Searching for a trend in the concentration levels of DHEA and its metabolites of several days, 
the correlation (Spearman’s correlation coefficient R) was tested between the day of 
collection of the urine sample and the concentration of the hormone. This was only performed 
for the sulphated forms of DHEA and 5-Andro for the treated calves, as for the other 
hormones and the free fraction concentration levels were too low or the linearity of the 
correlation could not be demonstrated by means of a scatterplot. Figure 5 shows the urinary 
levels of the sulphated forms of DHEA and 5-Andro of the separate calves of the two groups 
during the 7 consecutive days of treatment. The concentrations of the first day of urine 
collection of the second group have been left out, because the urine was taken after 8 hours 
instead of 24 hours like the other days and therefore showed much higher concentrations. The 
concentration of DHEA of the intramuscularly treated calf of group 2 showed a positive 
correlation (p<0.05 and R=0.86) with the days of treatment, meaning that the concentration 
increased as the calf was treated more days. The intramuscularly treated calf of group 1 did 
not show this correlation. We have no straightforward explanation, but the calf in group 2 was 
treated in the winter in contrast with the calf in group 1 that received the treatment in the 
summertime. Therefore the second calf had more adipose tissue, possibly retaining the DHEA 
longer and releasing more DHEA after a few days, resulting in higher DHEAS concentration 
in the urine. A positive correlation, but to a lesser extent, was also seen in this IM treated calf 
of group 2 for 5-Andro (p=0.05 and R=0.75). In contrast with the intramuscularly treated 
group, the orally treated group showed a steady-state condition.  
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CONCLUSIONS 
Sulphates, glucuronides and free forms were analyzed separately in order to gather 
information about the distribution of DHEA and its metabolites over these three forms. In 
general our results show that DHEAS constitute the largest proportion of urinary levels of 
DHEA. This was also found in humans, where DHEA is rapidly converted into DHEAS, 
which can be converted back to DHEA by peripheral sulphatases [17]. In this way DHEAS 
serves as a large precursor reservoir for the production of androgens and estrogens in non-
reproductive tissues [18]. The free form of DHEA was present to a much lesser extent than 
the sulphated form and DHEA-glucuronides were negligible and in most cases not 
quantifiable because concentrations were below the limit of detection. The same is valid for 
the determined DHEA metabolites: mainly present as sulphoconjugates, hardly in their free 
form, and negligible as glucuronides. There was no statistically significant difference between 
the levels of all target hormones in sulphated and free forms when comparing the orally 
treated with the intramuscularly treated group. When comparing the control group with the 
treated groups a statistically significant difference was obtained for sulphated DHEA and 5-
Andro and the free form of DHEA and α-T for the orally treated group and sulphated and free 
form of DHEA, 5-Andro and α-T for the intramuscularly treated group. These findings 
confirm that administered DHEA metabolizes mainly by the ∆ 5-pathway with 5-Andro as the 
intermediate and that the metabolisation by the ∆ 4-pathway with AED as the intermediate is 
hardly increased. 
No elevated levels of sulphated or free β-T were observed after administered DHEA, either 
oral or IM. This seems strange, as levels of α-T were increasing, while α-T is considered as 
the main metabolite of β-T from the action of 3β-hydroxysteroid dehydrogenase. However, 
these results are in accordance with the findings obtained by administration of DHEA to the 
gelding and the mare where there was a high conversion to 5-Andro and a much lower 
conversion to α- and β-T [19]. These results are also confirmed in humans where ingested 
DHEA was rapidly metabolized to 5-Andro [20].  
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Fig. 1 : Biosynthesis of 17β-Testosterone 
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Fig. 2 : Study design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 : Urinary levels  of the sulphated form of DHEA  (A), 5-Andro (B), α-T (C) and β-T (D) of  the 
control group (control, n=29), intramuscularly treated group (IM, n=14) and orally treated group (oral, 
n=13) 
o Outlier, * extreme  value 
A) B) 
 
C) D) 
 
 
 
 
 
 
 
 
 
 
Fig. 4 : Urinary levels  of the free form of DHEA  (A), 5-Andro (B), α-T (C), β-T (D) and AED (E) of  
the control group (control, n=29), intramuscularly treated group (IM, n=14) and orally treated group 
(oral, n=13) 
o Outlier, * extreme  value 
A)     B) 
    
 C) D) 
 
 E) 
 
Fig. 5 : Urinary levels of DHEA (A) and 5-Andro (B) of the 7 consecutive days of treatment 
from two treated calves of group 1 (filled triangles) and two treated calves of group 2 (open 
squares) 
A) 
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Table 1 : Gradient elution program for the separation of the precursors 
and metabolites of DHEA 
 
   
Time(min) Flow rate    
 (mL min-1) %A %B Curve 
 0 0.3 45 55 Initial 
 1 0.3 45 55 1 
 8 0.3 40 60 9 
13 0.3 40 60 1 
14 0.3 0 100 6 
22 0.3 0 100 1 
23 0.3 45 55 6 
30 0.3 45 55 1 
A : water/MeOH/FA (89.7/10/0.3); B : MeOH/FA (99.7/0.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 : Precursor and product ions. cone voltages and collision energies 
for each transition monitored in MRM (ESI+) analysis   
Compound Precursor Molecular Cone Product Collision 
 ion (m/z) Ion voltage 
(V) 
ion (m/z) energy (eV) 
T (α and β) 289.4 [M+H]+ 18 109.1* 33 
    97.1 
DHEA 253.4 [M+H-2H2O]+ 25 225.0 15 
    197.0* 17 
AED 287.2 [M+H]+ 36 109.3* 18 
    97.2 
5-Andro 273.4 [M+H-H2O]+ 27 255.3* 10 
    159.2 12 
Preg 317.3 [M+H]+ 24 281.4* 15 
    255.3 13 
OH-Preg 333.2 [M+H]+ 22 297.6* 10 
    133.2 18 
MT-D3 306.0 [M+H]+ 50 109.0* 30 
    97.0 
NT-D3 278.0 [M+H]+ 45 109.0* 28 
    83.0 
*Most abundant product ion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3a : Basal urinary concentrations (free and sulfated form) of DHEA  
and its metabolites of the calves included in group 1 before treatment  
 n Mean ± SE Median Minimum Maximum 
  (ng.mL-1) (ng.mL-1) (ng.mL-1) (ng.mL-1) 
Free form of      
DHEA 24 0.0 ± 0.0 0.0 0.0 0.0 
5-Andro 24 0.3 ± 0.9 0.0 0.0 3.9 
α-T  24 0.7 ± 0.9 0.5 0.0 4.9 
β-T  24 0.1 ± 0.2 0.0 0.0 0.5 
AED 24 0.4 ± 0.3 0.5 0.0 1.3 
Sulfated form of      
DHEA 26 45.6 ± 40.7 40.8 4.2 131.4 
5-Andro 26 29.9 ± 32.6 21.3 0.0 132.9 
α-T  26 9.1 ± 11.9 3.2 0.0 39.6 
β-T  26 2.5 ± 4.3 0.4 0.0 16.5 
      
 
Table 3b : Basal urinary concentrations (free and sulfated form) of DHEA  
and its metabolites of the calves included in group 2 before treatment  
 n Mean ± SE Median Minimum Maximum 
  (ng.mL-1) (ng.mL-1) (ng.mL-1) (ng.mL-1) 
Free form of      
DHEA 7 0.0 ± 0.0 0.0 0.0 0.0 
5-Andro 7 0.0 ± 0.0 0.0 0.0 0.0 
α-T  7 0.3 ± 0.4 0.0 0.0 0.8 
β-T  7 0.2 ± 0.3 0.0 0.0 0.5 
AED 7 0.4 ± 0.2 0.5 0.0 0.5 
Sulfated form of      
DHEA 6 43.9 ± 49.1 23.1 11.8 138.2 
5-Andro 6 70.2 ± 63.9 69.8 0.0 158.7 
α-T  6 72.2 ± 49.5 57.6 15.5 134.0 
β-T  6 8.4 ± 7.2 6.9 1.5 22.2 
      
 
 
 
 
 
 
 
 
 
 
Table 4 : Urinary concentrations (free and sulfated form) of DHEA and its metabolites   
of the control animals before and during the period of treatment       
 Before or during n Mean ± SE Median Minimum Maximum  
  treatment   (ng.mL
-1) (ng.mL-1) (ng.mL-1) (ng.mL-1)  
Free form of        
DHEA before 17 0.0 ± 00 0.0 0.0 0,0  
 during 29 0.3 ± 0.6 0.0 0.0 2.4  
5-Andro before 17 0.4 ± 1.1 0.0 0.0 3.9  
 during 29 0.1 ± 0.6 0.0 0.0 3.2  
α-T* before 14 1.0 ± 1.2 0.6 0.0 4.9  
 during 29 0.6 ± 0.6 0.5 0.0 1.6  
β-T*  before 14 0.2 ± 0.2 0.0 0.0 0.5  
 during 29 0.3 ± 0.4 0.0 0.0 1.0  
AED before 17 0.5 ± 0.3 0.5 0.0 1.3  
 during 29 1.4 ± 2.9 0.5 0.0 18.4  
Sulfated form of        
DHEA before 17 43.2 ± 36.1 42.5 6.2 131.4  
 during 29 51.1 ± 46.7 34.7 0,0 171.4  
5-Andro before 17 28.1 ± 31.2 15.7 0,0 118.8  
 during 29 75.8 ± 63.7 72.4 0,0 215.9  
α-T*  before 15 7.6 ± 10.0 2.6 0,0 32.1  
 during 29 12.7 ± 15.4 4.8 0,0 47.1  
β-T*  before 15 1.5 ± 2.6 0.3 0,0 9.9  
  during 29 1.1 ± 2.9 0.1 0,0 13.8  
* : includes only data from group 1        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
